- Home
- BLFS vs ERAS Comparison
BLFS vs ERAS Comparison
Compare BLFS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | ERAS |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1989 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLFS | ERAS |
|---|---|---|
| Price | $22.29 | $12.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $32.00 | $5.78 |
| AVG Volume (30 Days) | 357.6K | ★ 6.5M |
| Earning Date | 03-02-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $100,144,000.00 | N/A |
| Revenue This Year | $18.45 | N/A |
| Revenue Next Year | $16.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 87.53 | N/A |
| 52 Week Low | $19.10 | $1.01 |
| 52 Week High | $29.62 | $12.57 |
Technical Indicators
Market Signals| Indicator | BLFS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 40.63 | 77.85 |
| Support Level | $21.45 | $11.41 |
| Resistance Level | $22.99 | $12.48 |
| Average True Range (ATR) | 1.09 | 0.72 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 21.19 | 91.50 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.